🇺🇸 FDA
Pipeline program

pelareorep, Tecentriq 840 mg concentrate for solution for infusion

REO 029

Phase 2 small_molecule active

Quick answer

pelareorep, Tecentriq 840 mg concentrate for solution for infusion for Patients with advanced or metastatic gastrointestinal (GI) tumors. is a Phase 2 program (small_molecule) at ONCOLYTICS BIOTECH INC with 1 ClinicalTrials.gov record(s).

Program details

Company
ONCOLYTICS BIOTECH INC
Indication
Patients with advanced or metastatic gastrointestinal (GI) tumors.
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials